Holliston

Harvard Bioscience Inc. said a weaker U.S. dollar compared to the British pound helped bump its third quarter revenues slightly.

A Holliston-based clinical research organization will be providing services to a Texas biopharmaceutical company.

Harvard Bioscience Inc. (NASDAQ:HBIO), a Holliston-based manufacturer of life sciences equipment, has acquired two companies for a total of $11 million, the company announced Wednesday. The deals are expected to boost the company's electrophysiology business.

After sidelining Gov. Deval Patrick's proposal to make alcohol licensing a purely local responsibility, the House on Monday quietly approved license requests for two licenses in Southborough.

Holliston-based Harvard Apparatus Regenerative Technology Inc. (HART) reported a net quarterly loss $2.5 million, or 32 cents per share, higher than $2.1 million it lost in the same period in 2013.

Harvard Bioscience said a focus on its global growth strategy and a weaker dollar compared to the British pound and the Euro helped boost revenue slightly, as the life sciences manufacturer brought in $27 million.

Fueled by an increase in stock-based compensation related to the company's spin-off from Harvard Bioscience last November, Holliston-based Harvard Apparatus Regenerative Technology, Inc. (HART) reported a net loss for the quarter of $3 million, or 39 cents per share; an increase from $2 million from for the same period in 2013.

Harvard Bioscience said winter weather dragged down first-quarter revenue slightly, as the life sciences manufacturer brought in $25.9 million, down 0.7 percent from $26.1 million in the first quarter of 2013.

Holliston-based LW Robbins, a direct response fundraising agency, acquired Texas-based data analytics company KerstenDirect Wednesday, the new company announced.

Holliston-based medical device manufacturer Harvard Bioscience will cut about 13 percent of its workforce around the world as part of a reorganization that it said will position the company to grow.